Unlike Pparg, which can exacerbate MASH progression, knockouts of Ppara are linked to MASLD development, while Pgc1a overexpression reduces hepatic lipid accumulation.35, 36, 37. Here, PPARGC1A is linked to metabolic dysfunction-associated steatotic liver disease.